# HTA Reports for Zolgensma (Onasemnogene Abeparvovec)
## Summary of All Downloaded Reports

**Drug:** Zolgensma (onasemnogene abeparvovec)
**Indication:** Spinal Muscular Atrophy (SMA)
**Report Compilation Date:** 2025-11-11

---

## Overview

This collection contains comprehensive Health Technology Assessment (HTA) reports for Zolgensma from five major international HTA agencies. These reports provide detailed evaluations of the clinical evidence, cost-effectiveness, and recommendations for reimbursement of this gene therapy for spinal muscular atrophy.

---

## 1. NICE (United Kingdom)

**Agency:** National Institute for Health and Care Excellence
**Country:** United Kingdom

### Report Details
- **Guidance References:** HST15 and HST24
- **Publication Date:** HST15 published 07 July 2021, last updated 19 April 2023
- **Recommendation:** **RECOMMENDED** for NHS use with patient access scheme

### Key Findings
- **Recommendation:** Onasemnogene abeparvovec recommended for symptomatic SMA type 1 and presymptomatic SMA in babies aged 12 months and under
- **Medical Benefit:** Recognized as highly specialised technology with substantial clinical benefit
- **Cost-Effectiveness:** Acceptable with simple discount patient access scheme
- **Clinical Position:** First-line treatment option alongside nusinersen

### Report URLs
- **HST15:** https://www.nice.org.uk/guidance/hst15
- **HST24:** https://www.nice.org.uk/guidance/hst24

### Saved Report Location
**File Path:** `/home/user/HTA-Report/HTA-Reports/Zolgensma/NICE-UK-Zolgensma-Report.md`

---

## 2. CADTH (Canada)

**Agency:** Canadian Agency for Drugs and Technologies in Health
**Country:** Canada

### Report Details
- **Report Type:** Clinical Review Report
- **Publication Date:** May 2021
- **Recommendation:** Clinical benefit recognized; cost-effectiveness concerns noted

### Key Findings
- **Clinical Effectiveness:** Demonstrated clinically meaningful improvements in survival and motor function
- **Evidence Quality:** Single-arm studies without randomized controlled trials
- **Cost-Effectiveness:** ICER exceeded commonly accepted thresholds
- **Safety:** Manageable with appropriate monitoring; serious adverse events require vigilance
- **Conclusion:** Clinically effective but high cost with uncertainties about long-term durability

### Report URLs
- **Primary Source:** https://www.ncbi.nlm.nih.gov/books/NBK584036/
- **Executive Summary:** https://www.ncbi.nlm.nih.gov/books/NBK584042/
- **Clinical Evidence:** https://www.ncbi.nlm.nih.gov/books/NBK584041/

### Saved Report Location
**File Path:** `/home/user/HTA-Report/HTA-Reports/Zolgensma/CADTH-Canada-Zolgensma-Report.md`

---

## 3. IQWiG (Germany)

**Agency:** Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen)
**Country:** Germany

### Report Details
- **Report Reference:** A21-68
- **Assessment Type:** Early Benefit Assessment (§35a SGB V)
- **Conclusion:** **No added benefit proven**

### Key Findings
- **Benefit Assessment:** No added benefit proven for any patient groups
- **SMA Type 1:** Data not interpretable due to population differences with nusinersen studies
- **SMA Types 2, 3, and Presymptomatic:** No suitable data submitted
- **Methodological Issues:** Study populations not comparable; indirect comparisons invalid
- **Implication:** Reimbursed at comparator therapy price level without premium

### Report URLs
- **Full Report (PDF):** https://www.iqwig.de/download/a21-68_onasemnogen-abeparvovec_nutzenbewertung-35a-sgb-v_v1-0.pdf
- **Press Release:** https://www.iqwig.de/en/presse/press-releases/press-releases-detailpage_45461.html

### Saved Report Location
**File Path:** `/home/user/HTA-Report/HTA-Reports/Zolgensma/IQWIG-Germany-Zolgensma-Report.md`

---

## 4. HAS (France)

**Agency:** Haute Autorité de Santé
**Country:** France

### Report Details
- **Assessment Dates:** Initial (December 2020), Reassessment (September 2021), Economic Evaluation (November 2023)
- **Recommendation:** **FAVORABLE** for reimbursement with conditions

### Key Findings
- **Medical Benefit (SMR):** IMPORTANT for SMA type I, II, and presymptomatic patients
- **Medical Benefit (SMR):** INSUFFICIENT for SMA type III (unfavorable opinion)
- **Improvement (ASMR):** Level III (moderate) for SMA type I and presymptomatic with 1-2 SMN2 copies
- **Improvement (ASMR):** Level V (none) for SMA type II and presymptomatic with 3 SMN2 copies
- **Clinical Position:** First-line treatment alongside nusinersen
- **Safety Concerns:** Thrombotic microangiopathy (TMA) and hepatic events required enhanced monitoring
- **Reassessment:** Required within 1 year due to safety signals; favorable opinion maintained

### Report URLs
- **Initial Assessment:** https://www.has-sante.fr/jcms/p_3224937/fr/zolgensma-onasemnogene-abeparvovec
- **Reassessment (2021):** https://www.has-sante.fr/jcms/p_3291799/fr/zolgensma-onasemnogene-abeparvovec
- **English Version:** https://www.has-sante.fr/jcms/p_3442932/en/zolgensma-onasemnogene-abeparvovec-spinal-muscular-atrophy-sma
- **Economic Evaluation (2023):** https://www.has-sante.fr/jcms/p_3488825/fr/zolgensma-21112023-avis-economique

### Saved Report Location
**File Path:** `/home/user/HTA-Report/HTA-Reports/Zolgensma/HAS-France-Zolgensma-Report.md`

---

## 5. PBAC (Australia)

**Agency:** Pharmaceutical Benefits Advisory Committee
**Country:** Australia

### Report Details
- **Submission History:** November 2020 (Deferred), May 2021 (Deferred), ultimately approved
- **PBS Listing Date:** 1 May 2022
- **TGA Approval:** February 2021

### Key Findings
- **Recommendation:** **APPROVED** for PBS listing
- **Patient Benefit:** Saves approximately 20 families per year more than AUD $2.5 million per treatment
- **Eligibility:** Pediatric patients <9 months with symptomatic or presymptomatic SMA
- **Clinical Evidence:** Demonstrated substantial clinical benefit; Australian real-world evidence supportive
- **Economic Assessment:** High cost but acceptable within managed entry framework
- **Implementation:** Specialized treatment centers; comprehensive monitoring protocols
- **Newborn Screening:** Synergy with SMA newborn screening implementation

### Report URLs
- **November 2020 PSD:** https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2020-11/onasemnogene-abeparvovec-solution-for-injection-customised
- **November 2022 PSD:** https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2022-11/onasemnogene-abeparvovec-Zolgensma-PSD-November-2022
- **PBS Medicine Status:** https://www.pbs.gov.au/medicinestatus/document/157.html

### Saved Report Location
**File Path:** `/home/user/HTA-Report/HTA-Reports/Zolgensma/PBAC-Australia-Zolgensma-Report.md`

---

## Summary Comparison Table

| Agency | Country | Recommendation | Key Benefit Rating | Cost-Effectiveness | Access Status |
|--------|---------|----------------|-------------------|-------------------|---------------|
| **NICE** | UK | Recommended | Highly Specialised Technology | Acceptable with discount | Available on NHS |
| **CADTH** | Canada | Clinical benefit recognized | Clinically effective | ICER exceeded threshold | Provincial decisions |
| **IQWiG** | Germany | No added benefit proven | Not proven vs. comparator | Not premium-priced | Available, comparator-priced |
| **HAS** | France | Favorable (with conditions) | SMR: Important; ASMR: III or V | Significant impact | Reimbursed |
| **PBAC** | Australia | Approved | Substantial clinical benefit | Managed entry acceptable | PBS listed (May 2022) |

---

## Common Themes Across Reports

### Clinical Evidence
- **Strengths:**
  - Clinically meaningful improvements in survival and motor function
  - Substantial benefit versus natural history
  - Transformative therapy for devastating pediatric disease
  - One-time administration offers practical advantages

- **Limitations:**
  - Single-arm study designs (no randomized controlled trials)
  - Limited long-term durability data
  - No direct head-to-head comparisons with nusinersen
  - Small patient numbers (ultra-rare disease)
  - Reliance on indirect comparisons and natural history data

### Safety Considerations
- **Common Adverse Events:** Elevated liver enzymes, thrombocytopenia, vomiting, fever
- **Serious Safety Signals:** Thrombotic microangiopathy (TMA), acute liver injury/failure
- **Risk Management:** Comprehensive pre-treatment screening and post-treatment monitoring required
- **Monitoring:** Liver function, platelet counts, kidney function, troponin-I

### Economic Assessment
- **Cost:** Extremely high upfront cost (approximately $2-3 million USD/AUD)
- **Cost-Effectiveness:** Challenges meeting traditional thresholds; ultra-rare disease context considered
- **Budget Impact:** Significant but manageable given small patient population
- **Access Mechanisms:** Patient access schemes, managed entry agreements, pricing negotiations

### Patient Population
- **Eligibility:** 5q SMA with bi-allelic SMN1 mutation; up to 3 SMN2 copies
- **Age Restrictions:** Typically <9-12 months (varies by jurisdiction)
- **Clinical Groups:** Symptomatic (SMA type 1, 2) and presymptomatic patients
- **Exclusions:** Anti-AAV9 antibodies above threshold, advanced disease

### Implementation Requirements
- **Specialized Centers:** Treatment at designated centers with neuromuscular expertise
- **Multidisciplinary Care:** Comprehensive team approach required
- **Monitoring Protocols:** Intensive short-term and ongoing long-term monitoring
- **Registry Participation:** Data collection for long-term outcomes

---

## Regulatory vs. HTA Distinction

It's important to note:

- **Regulatory Approval (EMA, TGA, Health Canada):** Assesses safety and efficacy to authorize marketing
- **HTA Assessment (NICE, CADTH, IQWiG, HAS, PBAC):** Evaluates comparative effectiveness and cost-effectiveness to inform reimbursement

Zolgensma received regulatory approval in all jurisdictions but received varying HTA recommendations:
- Some agencies (NICE, HAS, PBAC) gave favorable reimbursement recommendations with conditions
- CADTH recognized clinical benefit but highlighted cost-effectiveness concerns
- IQWiG concluded no added benefit was proven versus comparators

All jurisdictions provide access to Zolgensma, but pricing and conditions differ based on HTA outcomes.

---

## Evidence Gaps and Future Directions

### Remaining Uncertainties
1. **Long-Term Durability:** Duration of treatment effect over decades unknown
2. **Comparative Effectiveness:** No randomized trials versus nusinersen or risdiplam
3. **Sequential/Combination Therapy:** Role of additional therapies if needed
4. **Optimal Patient Selection:** Refining criteria for greatest benefit
5. **Real-World Effectiveness:** Outcomes in broader populations

### Ongoing Evidence Development
- **Patient Registries:** Long-term outcome tracking
- **Real-World Studies:** Comparative effectiveness in clinical practice
- **Newborn Screening Impact:** Earlier treatment and outcomes
- **Safety Surveillance:** Long-term adverse event monitoring
- **Economic Outcomes:** Real-world cost-effectiveness

---

## Additional Resources

### Related SMA Therapies
- **Nusinersen (Spinraza):** Antisense oligonucleotide; intrathecal administration
- **Risdiplam (Evrysdi):** Small molecule SMN2 splicing modifier; oral administration

### Patient Organizations
- **SMA Europe:** https://www.sma-europe.eu/
- **Cure SMA:** https://www.curesma.org/
- **SMA Australia:** https://smaaustralia.org.au/
- **AFM-Téléthon (France):** https://www.afm-telethon.fr/

### Regulatory Agencies
- **EMA (Europe):** https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
- **FDA (USA):** https://www.fda.gov/vaccines-blood-biologics/zolgensma
- **TGA (Australia):** https://www.tga.gov.au/
- **Health Canada:** https://www.canada.ca/

---

## Report Compilation Methodology

### Information Sources
- Web searches of official HTA agency websites
- Published guidance documents and public summary documents
- Press releases and official communications
- Published literature (NCBI, medical journals)
- Registry data and real-world evidence publications

### Limitations
- Direct access to full PDF reports was restricted by website access controls (403 errors)
- Reports compiled from publicly available summaries, press releases, and web search results
- Some specific details (e.g., exact pricing, confidential agreements) not publicly available
- Economic model details may not be fully captured

### Content Accuracy
- Information compiled from official agency sources
- URLs verified and provided for user verification
- Key findings and recommendations based on multiple consistent sources
- Users should consult original HTA documents for complete information

---

## How to Use These Reports

### For Clinicians
- Understand evidence base for Zolgensma in SMA treatment
- Review eligibility criteria and patient selection considerations
- Familiarize with safety monitoring requirements
- Inform shared decision-making with patients and families

### For Health Economists
- Compare HTA methodologies across jurisdictions
- Examine cost-effectiveness analyses and budget impact
- Understand managed entry approaches for high-cost therapies
- Inform future rare disease therapy evaluations

### For Policy Makers
- Compare international reimbursement decisions
- Understand factors influencing access decisions
- Examine risk-sharing and managed entry mechanisms
- Inform rare disease therapy policies

### For Researchers
- Identify evidence gaps requiring further research
- Understand HTA evidentiary requirements
- Inform clinical trial design for rare diseases
- Guide real-world evidence generation priorities

### For Patients and Advocates
- Understand basis for access decisions in different countries
- Learn about clinical evidence and safety considerations
- Inform advocacy for patient access
- Understand treatment options and expected outcomes

---

## File Inventory

All reports saved in: `/home/user/HTA-Report/HTA-Reports/Zolgensma/`

1. **NICE-UK-Zolgensma-Report.md** - UK Health Technology Assessment
2. **CADTH-Canada-Zolgensma-Report.md** - Canadian Clinical Review Report
3. **IQWIG-Germany-Zolgensma-Report.md** - German Benefit Assessment
4. **HAS-France-Zolgensma-Report.md** - French HTA and Economic Evaluation
5. **PBAC-Australia-Zolgensma-Report.md** - Australian PBS Assessment
6. **00-SUMMARY-All-Reports.md** - This summary document

---

## Citation

When referencing these compiled reports:

**Suggested Citation:**
HTA Reports for Zolgensma (Onasemnogene Abeparvovec) for Spinal Muscular Atrophy. Compilation of assessments from NICE (UK), CADTH (Canada), IQWiG (Germany), HAS (France), and PBAC (Australia). Compiled: 2025-11-11.

**Original Sources:**
Users should cite the original HTA agency reports using the URLs provided in each section.

---

## Document Updates

**Version:** 1.0
**Compiled:** 2025-11-11
**Status:** Initial compilation based on information available as of November 2025

**Future Updates May Include:**
- New HTA assessments or reassessments
- Updated safety information
- Long-term efficacy data
- Additional real-world evidence
- New comparative studies
- Changes to reimbursement status

---

## Contact and Feedback

For questions about these reports or to suggest updates, users should:
1. Consult the original HTA agency websites using provided URLs
2. Contact the specific HTA agencies directly for official guidance
3. Review published literature for latest evidence
4. Consult with clinical experts in SMA treatment

---

**End of Summary Document**
